The outcomes from the July 2014 PBAC meeting have been added to the MAESTrO Australia PBAC database.

There are 70 outcomes from the July 2014 meeting:

• The single entry (recommendation) for panitumumab (Vectibix) has three outcomes (two for panitumumab and one for cetuximab)
• The single entry (recommendation) for escitalopram has three outcomes; one for each of the three patient populations; depression, generalised anxiety disorder and social anxiety disorder
• The single entry (deferral) for golimumab/infliximab/ustekinumab has ten outcomes: three outcomes for three patient populations for golimumab (RS, AS and PsA), six outcomes for six patient populations for infliximab (RS, AS, PsA, Ps, CD and UC) & one outcome for one patient population for ustekinumab (Ps)

Under these assumptions, there are:

• 41 recommendations (59%)
• 17 rejections (24%)
• 12 deferrals (17%)